Skip to main content

Immatics N.V.

IMTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001809196

In the last 90 days, Immatics N.V. insiders filed 1 open-market purchase and 0 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $1.01B in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Immatics N.V. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of IMTX: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders7670−6
Shares91.4M93.1M+1.74M (+1.9%)
Value$412.1M$500.9M+$88.8M (+21.6%)

New holders (17)

Institutions that held Immatics N.V. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to IMTX in Q2 2025
InstitutionSharesValue% of portfolio
Sectoral Asset Management Inc332,270$1.79M1.18%
MYDA Advisors LLC120,000$645.6K0.18%
Alps Advisors Inc65,582$352.8K0.00%
SummitTX Capital, L.P.60,920$327.8K0.01%
Ikarian Capital, LLC49,396$265.8K0.09%
JustInvest LLC43,969$236.6K0.00%
Fox Run Management, L.L.C.25,233$135.8K0.02%
Engineers Gate Manager LP23,133$124.5K0.00%
Mariner, LLC13,740$73.9K0.00%
Gsa Capital Partners LLP12,557$68.0K0.00%
Vontobel Holding Ltd.11,000$59.2K0.00%
Skopos Labs, Inc.1,820$9.79K0.00%
Simplex Trading, LLC1,690$9.00K0.00%
Tower Research Capital LLC (TRC)1,081$5.82K0.00%
Advisor Group Holdings, Inc.337$1.81K0.00%
Farther Finance Advisors, LLC335$1.80K0.00%
Raymond James Financial Inc200$1.08K0.00%

Sold out (23)

Institutions that held Immatics N.V. at the end of Q1 2025 and filed for Q2 2025 without it.